The collaboration will utilize Sosei Heptares' GPCR target proteins, which have been isolated and stabilized using the company's stabilized receptor platform. Twist will leverage its antibody libraries, including two synthetic GPCR-focused antibody libraries, and apply its bioinformatics approaches.

Sosei Heptares will hold exclusive, full global rights to develop and commercialize any antibody leads identified and directed to the targets of interest. Twist will be eligible for an upfront payment, ongoing R&D costs, and future payments based on the achievement of predefined development milestones, the companies said.

No financial terms of the agreement were disclosed.

Twist Bioscience to acquire Abveris for $190M
Twist Bioscience has entered into an agreement to purchase Abveris, a private in vivo antibody discovery firm, for $190 million.

Twist launches new biotech firm
Twist Bioscience has launched a new biotechnology firm, Revelar Biotherapeutics, to develop and market an antibody discovered by Twist that neutralizes...

Twist Bioscience, Broad Institute partner
Twist Bioscience and the Broad Institute have created a custom next-generation sequencing target enrichment exome panel to be used to research cancer...

Twist, Centogene to develop rare disease assay kits
Twist Bioscience and Centogene have signed a contract to collaborate on the development and commercialization of custom assay kits for rare diseases.